Management of type-2 Diabetes With Anti-Platelet Therapies: Special Reference to Aspirin

Front Biosci (Schol Ed). 2011 Jan 1;3:1-15. doi: 10.2741/s127.


Adult onset diabetes currently affects 380 million individuals worldwide and is expected to affect 380 million by 2025. Major defects contributing to this complex disease are insulin resistance and beta cell dysfunction. More than 80% of patients professing to type-2 diabetes are insulin resistant. Recent studies have shown that the Indian subcontinent ranks very high in the occurrence of Diabetes and Coronary artery disease (1, 2, 3). Patients with Type 2 diabetes carry an equivalent cardiovascular risk to that of a non-diabetic individual who has already experienced a coronary event. The risk of coronary artery disease in any given population seems to be 2-3 times higher in diabetics than non-diabetics. Inflammation, platelet activation, endothelial dysfunction and coagulation are the four processes, whose interplay determines the development of cardiovascular disease. In this article, we provide a brief overview on platelet physiology, vascular dysfunction, platelet hyper-function, and the role of platelet related clinical complications in diabetes mellitus and what is know about the management of this complex disease with anti-platelet drugs such as aspirin and Clopidogrel.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Arachidonic Acid / metabolism
  • Aspirin / therapeutic use*
  • Blood Platelets / physiology*
  • Clopidogrel
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Resistance
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Thienopyridines / therapeutic use
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Vascular Diseases / etiology
  • Vascular Diseases / prevention & control*


  • Platelet Aggregation Inhibitors
  • Thienopyridines
  • Arachidonic Acid
  • Clopidogrel
  • Ticlopidine
  • Aspirin